Pembrolizumab plus chemotherapy in triple-negative breast cancer

Lancet. 2021 Jul 3;398(10294):24. doi: 10.1016/S0140-6736(21)00380-9.

¹ Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Electronic address: [email protected].
² Department of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
³ Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

No abstract available

Publication types